



FIG. 1


Round 3



Round 2



Round 1



- Tumor only
- Mock
- GFP
- InsR
- CD27
- TCF1

FIG. 2




FIG. 3




FIG. 4A





FIG. 4B

effector count of
entire tumor mass



Effector
Vehicle
1. TRAC_CAR
2. TRAC_CAR-sIL2
3. TRAC_CAR-IL15RF
4. TRAC_CAR-IL7RF
5. TRAC_CAR-IL7RF, CD38_CD27
6. TRAC_CAR-IL7RF, CD38_TCF7
7. TRAC_CAR-IL7RF-IL15RaF
Primary CAR T

FIG. 5A




FIG. 5B

FIG. 6A





FIG. 6B







FIG. 7

*Progressive and titrated
expression of ADR*



TRAC mRNA during iT differentiation






FIG. 8

FIG. 9

*Appropriate differentiation of
ADR+ CAR iT cells*








FIG. 11A

CD58 KO synergizes with ADR to resist allogeneic rejection




FIG. 11B




FIG. 12

TRAC regulated IL-2 production during
steady state conditions

TRAC regulated IL-2 production following
CAR activation




FIG. 13A




FIG. 13B




FIG. 14A




FIG. 14B

FIG. 14C

FIG. 14D





FIG. 15A



CAR expression at the end of Round 1





FIG. 16A




FIG. 16B





FIG. 17






FIG. 19A






FIG. 19B






FIG. 21




FIG. 22A





FIG. 22B

BCMA 1xx-
TCF1-
CD38(CD28TM)BBz



BCMA 1xx-
TCF1




FIG. 22C